Cargando…
Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation
Renal transplantation is now the best treatment for end-stage renal failure. To avoid rejection and prolong graft function, organ recipients need immunosuppressive therapy. The immunosuppressive drugs used depends on many factors, including time since transplantation (induction or maintenance), aeti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298917/ https://www.ncbi.nlm.nih.gov/pubmed/37373448 http://dx.doi.org/10.3390/ijms241210301 |
_version_ | 1785064234705485824 |
---|---|
author | Szumilas, Kamila Wilk, Aleksandra Wiśniewski, Piotr Gimpel, Anna Dziedziejko, Violetta Kipp, Markus Pawlik, Andrzej |
author_facet | Szumilas, Kamila Wilk, Aleksandra Wiśniewski, Piotr Gimpel, Anna Dziedziejko, Violetta Kipp, Markus Pawlik, Andrzej |
author_sort | Szumilas, Kamila |
collection | PubMed |
description | Renal transplantation is now the best treatment for end-stage renal failure. To avoid rejection and prolong graft function, organ recipients need immunosuppressive therapy. The immunosuppressive drugs used depends on many factors, including time since transplantation (induction or maintenance), aetiology of the disease, and/or condition of the graft. Immunosuppressive treatment needs to be personalised, and hospitals and clinics have differing protocols and preparations depending on experience. Renal transplant recipient maintenance treatment is mostly based on triple-drug therapy containing calcineurin inhibitors, corticosteroids, and antiproliferative drugs. In addition to the desired effect, the use of immunosuppressive drugs carries risks of certain side effects. Therefore, new immunosuppressive drugs and immunosuppressive protocols are being sought that exert fewer side effects, which could maximise efficacy and reduce toxicity and, in this way, reduce both morbidity and mortality, as well as increase opportunities to modify individual immunosuppression for renal recipients of all ages. The aim of the current review is to describe the classes of immunosuppressive drugs and their mode of action, which are divided by induction and maintenance treatment. An additional aspect of the current review is a description of immune system activity modulation by the drugs used in renal transplant recipients. Complications associated with the use of immunosuppressive drugs and other immunosuppressive treatment options used in kidney transplant recipients have also been described. |
format | Online Article Text |
id | pubmed-10298917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102989172023-06-28 Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation Szumilas, Kamila Wilk, Aleksandra Wiśniewski, Piotr Gimpel, Anna Dziedziejko, Violetta Kipp, Markus Pawlik, Andrzej Int J Mol Sci Review Renal transplantation is now the best treatment for end-stage renal failure. To avoid rejection and prolong graft function, organ recipients need immunosuppressive therapy. The immunosuppressive drugs used depends on many factors, including time since transplantation (induction or maintenance), aetiology of the disease, and/or condition of the graft. Immunosuppressive treatment needs to be personalised, and hospitals and clinics have differing protocols and preparations depending on experience. Renal transplant recipient maintenance treatment is mostly based on triple-drug therapy containing calcineurin inhibitors, corticosteroids, and antiproliferative drugs. In addition to the desired effect, the use of immunosuppressive drugs carries risks of certain side effects. Therefore, new immunosuppressive drugs and immunosuppressive protocols are being sought that exert fewer side effects, which could maximise efficacy and reduce toxicity and, in this way, reduce both morbidity and mortality, as well as increase opportunities to modify individual immunosuppression for renal recipients of all ages. The aim of the current review is to describe the classes of immunosuppressive drugs and their mode of action, which are divided by induction and maintenance treatment. An additional aspect of the current review is a description of immune system activity modulation by the drugs used in renal transplant recipients. Complications associated with the use of immunosuppressive drugs and other immunosuppressive treatment options used in kidney transplant recipients have also been described. MDPI 2023-06-18 /pmc/articles/PMC10298917/ /pubmed/37373448 http://dx.doi.org/10.3390/ijms241210301 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Szumilas, Kamila Wilk, Aleksandra Wiśniewski, Piotr Gimpel, Anna Dziedziejko, Violetta Kipp, Markus Pawlik, Andrzej Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title | Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title_full | Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title_fullStr | Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title_full_unstemmed | Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title_short | Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation |
title_sort | current status regarding immunosuppressive treatment in patients after renal transplantation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298917/ https://www.ncbi.nlm.nih.gov/pubmed/37373448 http://dx.doi.org/10.3390/ijms241210301 |
work_keys_str_mv | AT szumilaskamila currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT wilkaleksandra currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT wisniewskipiotr currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT gimpelanna currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT dziedziejkovioletta currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT kippmarkus currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation AT pawlikandrzej currentstatusregardingimmunosuppressivetreatmentinpatientsafterrenaltransplantation |